Repository logo
 

Human brain changes after first psilocybin use.

Published version
Peer-reviewed

Repository DOI


Change log

Abstract

Psychedelics have robust effects on acute brain function and long-term behavior but whether they also cause enduring functional and anatomical brain changes is largely unknown. In an exploratory, placebo-controlled, within-subjects, electroencephalography (EEG), and magnetic resonance imaging (MRI) study in 28 healthy, entirely psychedelic-naive participants, anatomical and functional brain changes are detected from one-hour to one-month after a single high-dose (25 mg) of psilocybin. Increases in cognitive flexibility, psychological insight, and well-being are seen at one-month. Diffusion tensor imaging (DTI) done before and one-month after 25 mg psilocybin reveals decreased axial diffusivity bilaterally in prefrontal-subcortical tracts that correlate with decreases in brain network modularity (fMRI) over the same month. Enduring functional brain changes are largely absent, but network modularity change (numerical decrease) negatively correlates with well-being change (significant increase), in line with previous findings in depression. Increased cortical signal entropy (EEG) at 1- and 2-hours post-dosing predicts improved psychological well-being at one-month. Next-day psychological insight mediates the entropy to well-being relationship. All effects are exclusive to 25 mg psilocybin; no effects occur with a 1 mg psilocybin placebo.

Description

Acknowledgements: This work was funded by philanthropic donations to the Centre for Psychedelic Research, Imperial College London. T.L. received an MRC-DTP Studentship, H.M.D. received an Imperial College London President’s PhD Scholarships. R.C.H. was supported by the Alex Mosley Charitable Trust and the Ralph Metzner Distinguished Professorship (UCSF). Further support was provided by The Beckley Foundation. Infrastructure support was provided by the NIHR Imperial Biomedical Research Centre and the NIHR Imperial Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. We thank Manca Peskar, Victoria Nygart and Mellissa Shukuroglou for their invaluable assistance on study visits; Dr. Roberta Murphy and Dr. Jonny Martell for clinical oversight; Dr. Rosalind Watts for advice, training and support on guiding and integration procedures; Dr. Robin Tyacke for controlled drug oversight; Joe Peill, Gregory Cooper, Katie Trinci and Pablo Mallaroni for their support with data analysis; and Bruna Giribaldi for advice and support.


Funder: Funded by philanthropic donations to the Centre for Psychedelic Research, Imperial College London, founded in April 2019. TL received an MRC-DTP Studentship, HMD received an Imperial College London President’s PhD Scholarships. RCH was supported by the Alex Mosley Charitable Trust between 2015 and April 2019. From April 2019 to July 2021, RCH was supported by donations to the Centre for Psychedelic Research at Imperial College London, upon its creation; and from July 2021 to present, RCH has been supported by The Ralph Metzner Distinguished Professorship at University of California San Francisco and philanthropic donations. Some further support for this study was provided by The Beckley Foundation. Infrastructure support was provided by the NIHR Imperial Biomedical Research Centre and the NIHR Imperial Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Journal Title

Nat Commun

Conference Name

Journal ISSN

2041-1723
2041-1723

Volume Title

17

Publisher

Springer Nature

Rights and licensing

Except where otherwised noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/